From March 27 to 29, Jinyao Pharmaceutical showcased its product Mojia Qingning Pills at the 2025 Grand Health Industry (Chongqing) Expo and the 10th Shuangpin Fair, where it also received multiple honors. Sun Hongming, Deputy General Manager of Health Technology, led the team to participate in the exhibition.

With the theme “Staying the Course · Embracing Innovation,” the 2025 Grand Health Industry Expo / Shuangpin Fair aimed to guide professionals in the pharmaceutical and healthcare sector to return to fundamentals, drive innovation, and leverage retail and channel service advantages to explore new models, new technologies, and new services, thereby reshaping growth momentum. The event attracted over 1,000 enterprises in the pharmaceutical and health industry, and experts and scholars from various provinces and cities gathered to discuss topics such as artificial intelligence and big health, 5G remote diagnosis and treatment, and the development of new productive forces in biomedicine in western China.

During the exhibition, Mojia Qingning Pills, a representative proprietary Chinese medicine product of Jinyao Pharmaceutical, attracted extensive attention and inquiries from professionals and customers. Adding to the achievements, at the 10th Shuangpin Fair Awards Ceremony, Mojia Qingning Pills won the “Family Essential Product Award” in recognition of its outstanding quality and market reputation; Jinyao Heping, a subsidiary of Jinyao Pharmaceutical, received the “Star Outstanding Partner Award”; and Sun Hongming was honored as “Elite Person of the Year”.

(Note: Mojia Qingning Pills is an over-the-counter medicine (OTC). Please read the package insert carefully and purchase/use it under the guidance of a pharmacist.)

Article by: Health Technology Company